other material
confidence high
sentiment positive
materiality 0.65
Skye Bioscience reports pro forma equity >$5M after $90M private placement
Skye Bioscience, Inc.
- Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).
- Sold real estate held by subsidiary Avalite Sciences, recording $1.14M gain in pro forma.
- Pro forma stockholders' equity rises to $82.5M from ($2.1M) deficit at Dec 31, 2023.
- Company believes it now meets Nasdaq's $5M minimum equity requirement for initial listing.